All AbMole products are for research use only, cannot be used for human consumption.
Quizartinib (AC220) is a orally-administered, potent and selective inhibitor of two receptor tyrosine kinases, FLT3 and KIT. Quizartinib (AC220) exhibits low nanomolar potency in biochemical and cellular assays and exceptional kinase selectivity, and in animal models is efficacious at doses as low as 1 mg/kg given orally once daily. While other agents showed some ability to clear leukemia from the circulating blood, AC220 has shown significant ability to clear leukemic cells from the bone marrow, where the disease originates. AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.
Patent. CN113549000A 2021 Oct 26.
Patent. CN113549000A
Quizartinib (AC220) purchased from AbMole
Drug Des Devel Ther. 2018 Apr 30;12:1009-1017.
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
Quizartinib (AC220) purchased from AbMole
 |
Source | Mol Cancer (2013). Figure 3. AC220 |
| Method | PCR | |
| Cell Lines | Ba/F3 cells | |
| Concentrations | 0 – 5000 nM | |
| Incubation Time | 48 h | |
| Results | Comparison of inhibition of cellular proliferation after quizartinib treatment revealed strong correlation between naturally occurring and engineered cell lines expressing identical mutant kinases |
 |
Source | Mol Cancer (2013). Figure 2. AC220 |
| Method | cell apoptosis assay | |
| Cell Lines | leukemia cell line | |
| Concentrations | 0 – 5000 nM | |
| Incubation Time | 48 h | |
| Results | This finding suggests that the distinct mutant-KIT isoform directly orchestrates sensitivity towards quizartinib. |
| Cell Experiment | |
|---|---|
| Cell lines | MV4-11 and RS4;11 cells |
| Preparation method | Cellular assays. MV4-11 and RS4;11 cells were cultured in Iscove media with 10% fetal bovine serum (FBS) and RPMI complete with 10% FBS, respectively. For proliferation assays, cells were cultured overnight in low serum media (0.5% FBS), then seeded in a 96-well plate at 40 000 cells per well. Inhibitors were added to the cells and incubated at 37°C for 72 hours. Cell viability was measured using the Cell Titer-Blue Cell Viability Assay from Promega. To measure inhibition of FLT3 autophosphorylation, cells were cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells were incubated with inhibitors for 2 hours at 37°C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand was added for 15 minutes after the 2-hour compound incubation. Cell lysates were prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates were incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody was used for electrochemiluminescence detection on the Meso Scale Discovery platform. |
| Concentrations | 0~10 µM |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | subcutaneous tumor model |
| Formulation | 22% hydroxypropyl-β-cyclodextrin |
| Dosages | 10 mg/kg |
| Administration | orally |
| Molecular Weight | 560.67 |
| Formula | C29H32N6O4S |
| CAS Number | 950769-58-1 |
| Solubility (25°C) | DMSO ≥100 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related FLT3 Products |
|---|
| KW-2449
KW-2449 is a novel multitargeted kinase inhibitor of FLT3, ABL and Aurora kinase with IC50 values of 6.6 nM, 14 nM and 48 nM. |
| Tandutinib
Tandutinib (MLN518, CT53518) is an orally active multitargeted tyrosine kinase inhibitor of FLT3 (IC50 = 0.22 μM), and it also inhibits c-Kit and PDGFR with IC50 values of 0.17 μM and 0.20 μM, respectively. Tandutinib has the ability to cross the blood-brain barrier. |
| FF-10101
FF-10101 is a novel irreversible FLT3 inhibitor. |
| TCS 359
TCS 359 is a potent FLT3 inhibitor with IC50 of 42 nM. |
| CGP52421
CGP52421 is a FLT3 inhibitor, which is also an metabolite of midostaurin (PKC412). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
